...
sngx-img

Soligenix Inc, Common Stock

SNGX

NAQ

$3.31

-$0.15

(-4.33%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$8.76M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
29.10K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.85
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.83 L
$19.2 H
$3.31

About Soligenix Inc, Common Stock

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSNGXSectorS&P500
1-Week Return3.44%-2.82%0.15%
1-Month Return-9.32%-4.22%1.78%
3-Month Return-3.5%-9.52%8.7%
6-Month Return-10.54%-3.45%12.24%
1-Year Return-67.11%5.62%30.9%
3-Year Return-98.16%3.8%30.19%
5-Year Return-98.89%39.68%91.72%
10-Year Return-99.9%105.02%203.2%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue4.63M2.36M824.27K948.91K839.36K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":50.96,"profit":true},{"date":"2021-12-31","value":17.8,"profit":true},{"date":"2022-12-31","value":20.5,"profit":true},{"date":"2023-12-31","value":18.13,"profit":true}]
Cost of Revenue3.57M1.82M728.64K550.82K742.05K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":51.04,"profit":true},{"date":"2021-12-31","value":20.42,"profit":true},{"date":"2022-12-31","value":15.44,"profit":true},{"date":"2023-12-31","value":20.8,"profit":true}]
Gross Profit1.06M538.50K95.63K398.09K97.31K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":50.68,"profit":true},{"date":"2021-12-31","value":9,"profit":true},{"date":"2022-12-31","value":37.47,"profit":true},{"date":"2023-12-31","value":9.16,"profit":true}]
Gross Margin22.95%22.82%11.60%41.95%11.59%[{"date":"2019-12-31","value":54.7,"profit":true},{"date":"2020-12-31","value":54.4,"profit":true},{"date":"2021-12-31","value":27.65,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":27.64,"profit":true}]
Operating Expenses11.17M19.03M13.06M14.50M7.80M[{"date":"2019-12-31","value":58.7,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":68.64,"profit":true},{"date":"2022-12-31","value":76.22,"profit":true},{"date":"2023-12-31","value":40.96,"profit":true}]
Operating Income(10.11M)(18.49M)(12.97M)(14.11M)(7.70M)[{"date":"2019-12-31","value":-1010742700,"profit":false},{"date":"2020-12-31","value":-1849114800,"profit":false},{"date":"2021-12-31","value":-1296611500,"profit":false},{"date":"2022-12-31","value":-1410603500,"profit":false},{"date":"2023-12-31","value":-769794000,"profit":false}]
Total Non-Operating Income/Expense290.13K50.21K(1.31M)(1.54M)(488.83K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":17.31,"profit":true},{"date":"2021-12-31","value":-452.28,"profit":false},{"date":"2022-12-31","value":-529.76,"profit":false},{"date":"2023-12-31","value":-168.49,"profit":false}]
Pre-Tax Income(9.97M)(18.53M)(13.42M)(14.95M)(7.91M)[{"date":"2019-12-31","value":-996626800,"profit":false},{"date":"2020-12-31","value":-1852541500,"profit":false},{"date":"2021-12-31","value":-1341571500,"profit":false},{"date":"2022-12-31","value":-1495327400,"profit":false},{"date":"2023-12-31","value":-790853300,"profit":false}]
Income Taxes(610.68K)(836.89K)(864.74K)(1.15M)(1.77M)[{"date":"2019-12-31","value":-61067600,"profit":false},{"date":"2020-12-31","value":-83689300,"profit":false},{"date":"2021-12-31","value":-86474200,"profit":false},{"date":"2022-12-31","value":-115493500,"profit":false},{"date":"2023-12-31","value":-176780300,"profit":false}]
Income After Taxes(9.36M)(17.69M)(12.55M)(13.80M)(6.14M)[{"date":"2019-12-31","value":-935559200,"profit":false},{"date":"2020-12-31","value":-1768852200,"profit":false},{"date":"2021-12-31","value":-1255097300,"profit":false},{"date":"2022-12-31","value":-1379833900,"profit":false},{"date":"2023-12-31","value":-614073000,"profit":false}]
Income From Continuous Operations(9.36M)(17.69M)(12.55M)(13.80M)(8.07M)[{"date":"2019-12-31","value":-935559200,"profit":false},{"date":"2020-12-31","value":-1768852200,"profit":false},{"date":"2021-12-31","value":-1255097300,"profit":false},{"date":"2022-12-31","value":-1379833900,"profit":false},{"date":"2023-12-31","value":-807439000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(9.36M)(17.69M)(12.55M)(13.80M)(6.14M)[{"date":"2019-12-31","value":-935559200,"profit":false},{"date":"2020-12-31","value":-1768852200,"profit":false},{"date":"2021-12-31","value":-1255097300,"profit":false},{"date":"2022-12-31","value":-1379833900,"profit":false},{"date":"2023-12-31","value":-614073000,"profit":false}]
EPS (Diluted)(7.35)(9.60)(4.65)(8.18)(0.97)[{"date":"2019-12-31","value":-735,"profit":false},{"date":"2020-12-31","value":-960,"profit":false},{"date":"2021-12-31","value":-465,"profit":false},{"date":"2022-12-31","value":-818,"profit":false},{"date":"2023-12-31","value":-97,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SNGX
Cash Ratio 2.17
Current Ratio 2.28

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SNGX
ROA (LTM) -45.14%
ROE (LTM) -139.80%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SNGX
Debt Ratio Lower is generally better. Negative is bad. 0.43
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.57

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SNGX
Trailing PE NM
Forward PE NM
P/S (TTM) 23.88
P/B 1.47
Price/FCF NM
EV/R 1.87
EV/Ebitda NM
PEG NM

FAQs

What is Soligenix Inc share price today?

Soligenix Inc (SNGX) share price today is $3.31

Can Indians buy Soligenix Inc shares?

Yes, Indians can buy shares of Soligenix Inc (SNGX) on Vested. To buy Soligenix Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SNGX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Soligenix Inc be purchased?

Yes, you can purchase fractional shares of Soligenix Inc (SNGX) via the Vested app. You can start investing in Soligenix Inc (SNGX) with a minimum investment of $1.

How to invest in Soligenix Inc shares from India?

You can invest in shares of Soligenix Inc (SNGX) via Vested in three simple steps:

  • Click on Sign Up or Invest in SNGX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Soligenix Inc shares
What is Soligenix Inc 52-week high and low stock price?

The 52-week high price of Soligenix Inc (SNGX) is $19.2. The 52-week low price of Soligenix Inc (SNGX) is $1.83.

What is Soligenix Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Soligenix Inc (SNGX) is

What is Soligenix Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Soligenix Inc (SNGX) is 1.47

What is Soligenix Inc dividend yield?

The dividend yield of Soligenix Inc (SNGX) is 0.00%

What is the Market Cap of Soligenix Inc?

The market capitalization of Soligenix Inc (SNGX) is $8.76M

What is Soligenix Inc’s stock symbol?

The stock symbol (or ticker) of Soligenix Inc is SNGX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top